skip to Main Content

PSMD11, PTPRM and PTPRB as Novel Biomarkers of Pancreatic Cancer Progression

PSMD11, PTPRM and PTPRB as Novel Biomarkers of Pancreatic Cancer Progression
Pancreatic ductal adenocarcinoma (PDAC) has the lowest survival rate of all major cancers. Surgery is the only curative intent therapy, but the majority of patients experience disease relapse. Thus, patients who do not benefit from highly morbid surgical resection needs to be identified and offered palliative chemotherapy instead.

In this pilot study, we aimed to identify differentially regulated proteins in plasma and plasma derived microparticles from PDAC patients with poor and good prognosis.Plasma and plasma derived microparticle samples were obtained before surgical resection from PDAC patients. Sequential Windowed Acquisition of all Theoretical fragment ion spectra – Mass Spectrometry (SWATH-MS) proteomic analysis was performed to identify and quantify proteins in these samples. Read more . . . 


Back To Top